CN103372000A - Chukrasone B在治疗或预防慢性心衰的药物中的应用 - Google Patents
Chukrasone B在治疗或预防慢性心衰的药物中的应用 Download PDFInfo
- Publication number
- CN103372000A CN103372000A CN2013102807773A CN201310280777A CN103372000A CN 103372000 A CN103372000 A CN 103372000A CN 2013102807773 A CN2013102807773 A CN 2013102807773A CN 201310280777 A CN201310280777 A CN 201310280777A CN 103372000 A CN103372000 A CN 103372000A
- Authority
- CN
- China
- Prior art keywords
- chukrasone
- heart failure
- chronic heart
- preparation
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229930187319 chukrasone Natural products 0.000 title claims abstract description 27
- 206010007558 Cardiac failure chronic Diseases 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 229940079593 drug Drugs 0.000 title abstract 3
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 abstract description 7
- 206010019280 Heart failures Diseases 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 3
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 4
- 241001156380 Chukrasia tabularis Species 0.000 description 3
- 108010087141 Kv1.2 Potassium Channel Proteins 0.000 description 3
- 102000006628 Kv1.2 Potassium Channel Human genes 0.000 description 3
- 238000007914 intraventricular administration Methods 0.000 description 3
- 239000003450 potassium channel blocker Substances 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 208000006193 Pulmonary infarction Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000007575 pulmonary infarction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310280777.3A CN103372000B (zh) | 2013-07-04 | 2013-07-04 | Chukrasone B在制备治疗或预防慢性心衰的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310280777.3A CN103372000B (zh) | 2013-07-04 | 2013-07-04 | Chukrasone B在制备治疗或预防慢性心衰的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103372000A true CN103372000A (zh) | 2013-10-30 |
CN103372000B CN103372000B (zh) | 2015-09-16 |
Family
ID=49458250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310280777.3A Active CN103372000B (zh) | 2013-07-04 | 2013-07-04 | Chukrasone B在制备治疗或预防慢性心衰的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103372000B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1980923A (zh) * | 2004-04-13 | 2007-06-13 | 安克进药物公司 | 多环吡啶作为钾离子通道调节剂 |
-
2013
- 2013-07-04 CN CN201310280777.3A patent/CN103372000B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1980923A (zh) * | 2004-04-13 | 2007-06-13 | 安克进药物公司 | 多环吡啶作为钾离子通道调节剂 |
Non-Patent Citations (1)
Title |
---|
LIU,H.B.ET AL.: "Chukrasone A and B:Potential Kv1.2Potassium Channel Blockers with New Skeletons from Chukrasia tabularis.", 《ORGANIC LETTERS》 * |
Also Published As
Publication number | Publication date |
---|---|
CN103372000B (zh) | 2015-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105412101A (zh) | Virosaines A在制备治疗或预防慢性心衰药物中的应用 | |
CN103585148B (zh) | Nitrosporeusines A在治疗或预防慢性心衰药物中的应用 | |
CN103599106B (zh) | Caesanines D在制备治疗或预防慢性心衰药物中的应用 | |
CN103372000A (zh) | Chukrasone B在治疗或预防慢性心衰的药物中的应用 | |
CN103393698B (zh) | Chukrasone A在制备治疗或预防慢性心衰的药物中的应用 | |
CN103356673B (zh) | Houttuynoid A在制备治疗或预防慢性心衰的药物中的应用 | |
CN103356686B (zh) | Houttuynoid B在制备治疗或预防慢性心衰的药物中的应用 | |
CN103356671B (zh) | Houttuynoid C在制备治疗或预防慢性心衰的药物中的应用 | |
CN103610672B (zh) | Hippolachnin A在治疗或预防慢性心衰药物中的应用 | |
CN103768050B (zh) | Eryngiolide A在治疗或预防慢性心衰的药物中的应用 | |
CN103550225B (zh) | Phyllanthoid A在制备治疗或预防慢性心衰药物中的应用 | |
CN103381180A (zh) | Houttuynoid E在治疗或预防慢性心衰的药物中的应用 | |
CN103356570A (zh) | Sarcaboside B在治疗或预防慢性心衰的药物中的应用 | |
CN103356548A (zh) | Sarcaboside A在治疗或预防慢性心衰的药物中的应用 | |
CN103356670A (zh) | Houttuynoid D在治疗或预防慢性心衰的药物中的应用 | |
CN102988347A (zh) | Aphanamixoid A在制备治疗或预防慢性心衰的药物中的应用 | |
CN103263421A (zh) | Myriberine A在制备治疗或预防慢性心衰药物中的应用 | |
CN103479621A (zh) | Neonectrolide A在制备治疗或预防慢性心衰药物中的应用 | |
CN103316028A (zh) | Polyflavanostilbene A在制备治疗或预防慢性心衰药物中的应用 | |
CN105395543A (zh) | Verrulactone C在制备治疗或预防慢性心衰药物中的应用 | |
CN105287452A (zh) | Periconianone A在制备治疗或预防慢性心衰药物中的应用 | |
CN104997766A (zh) | 一种治疗或预防慢性心衰药物及其应用 | |
CN105412064A (zh) | Salvadione C在制备治疗或预防慢性心衰药物中的应用 | |
CN103356669A (zh) | Houttuynoid A在治疗或预防急性心衰的药物中的应用 | |
CN103463006A (zh) | Racemosins A在制备治疗或预防慢性心衰药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171115 Address after: 401120 Chongqing Yubei District Food City Avenue 18 Chongqing advertising industrial park office space Patentee after: Chongqing San Mou science and Technology Development Co., Ltd. Address before: 210009 Gulou District, Jiangsu, Nanjing Gu Ping Kong, No. 4 Patentee before: Ding Shengyu |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201222 Address after: 224200 No.88 Gangcheng Avenue, Dongtai coastal economic zone, Yancheng City, Jiangsu Province Patentee after: Dongtai Haibin science and Technology Pioneer Park Management Co., Ltd Address before: 401120 office building of Chongqing advertising industrial park, No.18, shifucheng Avenue, Yubei District, Chongqing Patentee before: CHONGQING SUMARTE TECHNOLOGY DEVELOPMENT Co.,Ltd. |